ORGSOrgenesis, Inc.

About Orgenesis, Inc. (ORGS)

Orgenesis, Inc. (ORGS) is a Biotechnology company headquartered in Germantown, MD, United States whose shares trade over-the-counter on the OTCQX tier.

We are a global biotech company working to unlock the potential of cell and gene therapies ("CGTs") in an affordable and accessible format. CGTs can be centered on autologous (using the patient's own cells) or allogenic (using master banked donor cells) and are part of a class of medicines referred to as advanced therapy medicinal products ("ATMPs"). We are mostly focused on autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care ("POCare"). This approach has the potential to overcome the limitations of traditional commercial manufacturing methods that do not translate well to commercial production of advanced therapies due to their cost prohibitive nature and complex logistics to deliver such treatments to patients (ultimately limiting the number of patients that can have access to, or can afford, these therapies).

Products and services

We have designed and built our POCare Platform - a scalable infrastructure of technology and services that ensures a central quality system, replicability and standardization of infrastructure and equipment, and centralized monitoring and data management. The platform is constructed on POCare Centers that serve as hubs that implement locally our POCare quality system, Good Manufacturing Practices (“GMP”), training procedures, quality control testing and incoming supply of materials. This platform is utilized by other parties, such as biotech companies and hospitals for the supply of their products. In addition, we have a pipeline of cell and gene therapies pipeline that includes investigational therapies and next-generation technologies that have the power to transform the way cancer and other unmet clinical needs are treated. Our pipeline is predominantly comprised of personalised autologous cell therapies, meaning that patients receive cells that originate from their own body, virtually eliminating the risk of an immune response and rejection.

ORGS key facts

Ticker symbol

ORGS

Market tier

OTCQX

Sector

Healthcare

Industry

Biotechnology

Headquarters

Germantown, MD, United States

Country of incorporation

US

Year of incorporation

2008

Employees

99

Estimated market cap

$11.95M (as of Apr 10, 2025)

Shares outstanding

6,568,145

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Latest filing

8K Report (Dec 24, 2024)

Orgenesis, Inc. leadership

• Vered Caplan — CEO
• Victor Miller — CFO
• Mark E. Goodman — Advisor
• Doug Karriker — Other
• Evan Fishman — Other

Explore more: Biotechnology stocks · Healthcare sector · OTCQX stocks · OTC stocks starting with O